Dr. Wade T. Iams, a researcher from the Vanderbilt Ingram Cancer Society Center, dives into the complexities of lung cancer treatment. He discusses a groundbreaking case where a patient developed resistance to lorlatinib due to a rare genetic alteration, RUFY1-RET. This revelation emphasizes the critical role of advanced genetic testing and the necessity for personalized cancer treatments. As cancer evolves, understanding resistance mechanisms becomes vital for effective precision oncology.